This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
compared with the current practice for the prevention and treatment of jaundice in newborn infants.
Outcomes assessed in the review
The outcomes assessed in the review were the probabilities of: a home nurse visit 1 to 2 days after discharge (including probabilities for referral for an office visit after the home nurse visit, laboratory testing after the office visit, hospitalisation for phototherapy after laboratory testing, and treatment with home phototherapy after laboratory testing); an office visit 1 to 2 days after discharge (including probabilities of laboratory testing after the office visit, hospitalisation for phototherapy after laboratory testing, and treatment with home phototherapy after laboratory testing); and not being examined by a health care provider in the 2 days after discharge.
Study designs and other criteria for inclusion in the review
Not reported.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Ten studies were included in the review.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The probability of a home nurse visit 1 to 2 days after discharge was 0.2 under current practice, 0.2 under the universal follow-up strategy, 0.1 under the predischarge serum bilirubin strategy, and 0.1 under the predischarge transcutaneous bilirubin strategy.
The probability of an office visit 1 to 2 days after discharge was 0.3 under current practice, 0.7 under the universal follow-up strategy, 0.5 under the predischarge serum bilirubin strategy, and 0.6 under the predischarge transcutaneous bilirubin strategy.
The probability of not being examined by health care provider in the 2 days of discharge was 0.5 under current practice,
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Methods used to derive estimates of effectiveness
Some estimates of effectiveness were based on authors' assumptions and interviews with paediatricians.
Estimates of effectiveness and key assumptions
The authors adjusted the probabilities of laboratory testing and receiving phototherapy treatment in their model so that approximately 2% of the cohort infants under the "current practice" strategy received phototherapy. They obtained the remaining probabilities from interviews with paediatricians who represented four group practices and who were interviewed about their practice patterns. Some of the probabilities for predischarge serum bilirubin and predischarge transcutaneous bilirubin were estimates based on the first author's knowledge about neonatal jaundice and its treatment, and on discussions with paediatric colleagues about likely paediatric changes in response to promulgated prevention strategies. The authors assumed that in all three prevention strategies, the threshold for treatment would be lowered.
Measure of benefits used in the economic analysis
The measure of benefits used appears to have been the estimated number of kernicterus cases prevented per year. The authors assumed that the effectiveness of each strategy in preventing kernicterus was the same.
Direct costs
The direct costs were derived from charges by applying a cost-to-charge ratio of 0.58, the Medicare state-wide average operating cost-to-charge ratio for an urban hospital in Vermont, USA. The charges included provider charges for laboratory tests, the costs for supplies for blood sampling, nursing time, the costs of transcutaneous bilirubinometry, the cost of the disposables for each infant tested, the charges for an office visit, the charges for home visits by skilled nurses, hospital charges and the charges for home phototherapy. Provider charges for laboratory tests and hospital charges per day were from the Fletcher Allen Health Care Hospital, Burlington, VT. The costs of transcutaneous bilirubinometry were from the company (Respironics, Murrysville, PA). The charges for an office visit were from the charges for paediatric office visits in Burlington, VT. The charges for home visits by skilled nurses were from the Visiting Nurses Association of Vermont. Savings resulting from the prevention of kernicterus were estimated on the basis of the average lifetime direct and indirect costs per person of cerebral palsy and mental retardation, discounted at 3%. The quantities and the costs were measured separately. All costs were estimated in 2002 dollars.
Statistical analysis of costs
No statistical analysis of the costs was reported.
Indirect Costs
Indirect costs, such as work-loss costs for the parents, were not included.
Currency

US dollars ($).
Sensitivity analysis
One-way sensitivity analyses were performed to investigate the true population incidence of kernicterus, which was unknown, and the relative risk reduction (RRR) with each strategy.
Estimated benefits used in the economic analysis
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At an annual incidence of 1:100,000 healthy term births and an RRR of 0.7, the universal follow-up, predischarge serum bilirubin and predischarge transcutaneous bilirubin strategies each led to 20 additional cases prevented per year for the cohort, compared with current practice.
Cost results
At an annual incidence of 1:100,000 healthy term births and an RRR of 0.7, the annual cost for the cohort was $152,392,631 with current practice.
The incremental annual cost for the cohort over current practice was $202,300,671 under the universal follow-up strategy, $112,580,535 under the predischarge serum bilirubin strategy, and $180,150,494 under the predischarge transcutaneous bilirubin.
Synthesis of costs and benefits
The cost per case prevented was highest with universal early follow-up ($10,321,463) and lowest with routine predischarge serum bilirubin screening ($5,743,905) .
The results of a one-way sensitivity analysis across a range of RRR assumptions (with a fixed kernicterus incidence of 1:100,000 live births) showed that estimates of the cost per case prevented ranged from $3,750,733 to $77,650,240 when the RRR was varied from 1.0 to 0.1, respectively, across the three strategies.
In all situations, at comparative incidence and relative risk figures, the highest costs resulted from the universal followup strategy and the lowest from the predischarge serum bilirubin strategy.
Authors' conclusions
Widespread implementation of these strategies is likely to increase health care costs significantly with uncertain benefits. It is premature to implement routine predischarge serum or transcutaneous bilirubin screening on a large scale. However, universal follow-up may have benefits beyond kernicterus prevention, which the authors stated were not included in their model.
CRD COMMENTARY -Selection of comparators
A justification was given for the comparator used (i.e. current practice). You should decide if this is a widely used health technology in your own setting.
Validity of estimate of measure of effectiveness
The effectiveness evidence used in this study was taken from the literature, supplemented by interviews with paediatricians and a several assumptions on the model parameters. A systematic review of the literature does not appear to have been undertaken.
Validity of estimate of measure of benefit
The measure of benefit was the cost per case prevented. The estimation of benefits was modelled. The instrument used to derive the measure of health benefit, a decision analytical model, was appropriate.
